Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy by Fahmueller, Yvonne Nadine et al.
RESEARCH ARTICLE Open Access
Predictive and prognostic value of circulating
nucleosomes and serum biomarkers in patients
with metastasized colorectal cancer undergoing
Selective Internal Radiation Therapy
Yvonne Nadine Fahmueller
1, Dorothea Nagel
1, Ralf-Thorsten Hoffmann
2,4, Klaus Tatsch
3,5, Tobias Jakobs
2,6,
Petra Stieber
1 and Stefan Holdenrieder
1,7*
Abstract
Background: Selective Internal Radiation Therapy (SIRT) is a new and effective locoregional anticancer therapy for
colorectal cancer patients with liver metastases. Markers for prediction of therapy response and prognosis are
needed for the individual management of those patients undergoing SIRT.
Methods: Blood samples were prospectively and consecutively taken from 49 colorectal cancer patients with
extensive hepatic metastases before, three, six, 24 and 48 h after SIRT to analyze the concentrations of
nucleosomes and further laboratory parameters, and to compare them with the response to therapy regularly
determined 3 months after therapy and with overall survival.
Results: Circulating nucleosomes, cytokeratin-19 fragments (CYFRA 21-1), carcinoembryonic antigen (CEA), C-
reactive protein (CRP) and various liver markers increased already 24 h after SIRT. Pretherapeutical levels of CYFRA
21-1, CEA, cancer antigen 19-9 (CA 19-9), asparate-aminotransferase (AST) and lactate dehydrogenase (LDH) as well
as 24 h values of nucleosomes were significantly higher in patients suffering from disease progression (N = 35)
than in non-progressive patients (N = 14). Concerning overall survival, CEA, CA 19-9, CYFRA 21-1, CRP, LDH, AST,
choline esterase (CHE), gamma-glutamyl-transferase, alkaline phosphatase, and amylase (all 0 h, 24 h) and
nucleosomes (24 h) were found to be prognostic relevant markers in univariate analyses. In multivariate Cox-
Regression analysis, the best prognostic model was obtained for the combination of CRP and AST. When 24 h
values were additionally included, nucleosomes (24 h) further improved the existing model.
Conclusion: Panels of biochemical markers are helpful to stratify pretherapeutically colorectal cancer patients for
SIR-therapy and to early estimate the response to SIR-therapy.
Keywords: Colorectal cancer, Selective Internal Radiation Therapy, Therapy response, Nucleosomes, Cancer
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Background
Colorectal cancer is the third most common cancer in
women and men worldwide [1] and accounts for almost
9% of all cancer deaths in the USA [2]. At time of
detection of the primary tumor, 15-20% of the patients
will already present with liver metastases, another 20%
will develop these metastases following treatment of the
primary tumor [3]. In 20% of these patients the liver
will be the only site of metastases at the time of death
[4]. Despite new treatment options nowadays, patients
with distant metastases of colorectal cancer just have a
five-year survival rate of 11% [2]. Resection of colorectal
liver metastases is a potential cure, but unfortunately
only a minority of patients (10-15%) is considered as
candidates for resection [5]. New local therapy options
such as radiofrequency ablation (RFA) and cryotherapy
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ble anymore. But also in these therapies, local recur-
rence rates are directly related to the diameter of the
lesions treated and considerably increase in lesions over
4 cm [6,7]. In disseminated liver metastases, surgical
resection as well as RFA and cryotherapy cannot be
applied anymore. In chemotherapy-refractory patients,
Selective Internal Radiation Therapy (SIRT) is a valuable
treatment option. Healthy liver tissue is very sensitive to
radiation limiting the dosage of external beam radiation
to 30-35 Gy to avoid possibly lethal radiation induced
liver disease [8]. As liver metastases tend to obtain their
blood supply rather from the hepatic artery than from
the portal vein [9], microspheres loaded with Yttrium 90
administered through the hepatic artery directly damage
t h et u m o ra n dr e l a t i v e l ys p a r et h er a d i a t i o ns e n s i b l e
liver tissue [10]. Thereby an average tumor dosage of
200-300 Gy is applied [11]. A study in metastasized col-
orectal cancer patients comparing SIRT and systemic
chemotherapy consisting of fluorouracil and folinic acid
with chemotherapy alone showed a significant improve-
ment in progression-free and overall survival associated
with SIRT, both for the total population studied as well
as for those patients with disease limited to the liver
[12]. However, some earlier studies reported that there
was an increase in toxicity with the use of SIRT [13].
Undesirable side effects of SIRT are rare and due to
misguided radiating microspheres into the stomach
causing gastrointestinal ulcers [14] and into the lungs
leading to radiation pneumonitis [15]. To prevent these
u n d e s i r a b l es i d ee f f e c t s ,a n angiography is performed
prior to SIRT to evaluate the individual vascular anat-
omy and to determine the appropriate placement for
the catheter tip. At the end of this procedure, 80-100
Mbq Technetium 99-macroaggregated albumin (Tc-99
m MAA) are administered [16]. As these gamma radia-
tion emitters have the same particle size compared to
the resin microspheres, they allow to predict micro-
sphere distribution and quantify hepato-pulmonary-
shunting by doing a scintigraphy shortly after the injec-
tion [17].
Up to now, there are only rare reports of small studies
on factors predicting the therapy outcome in colorectal
cancer patients with liver metastases undergoing SIR
treatment. Only recently, Dunfee BL et al. reported that
response on imaging one month after radioembolization
based on World Health Organisation criteria may be a
favourable prognostic marker [18]. Having a new power-
ful but also potentially toxic treatment for liver metas-
tases at hand, prognostic markers are urgently needed
to choose pretherapeutically the best treatment available
for every patient. Furtheron, early information on the
efficacy of the therapy during the first days after SIRT
application would be highly appreciated as therapy may
be intensified e.g. by chemotherapy or new biological
drugs - all the more as the regular staging of the
patients by imaging is only done about 3 months after
SIRT application.
For both purposes, circulating biochemical markers in
the blood are supposed to be most appropriate as that
are related to both cancer biology and therapy efficacy.
Furtheron, they can be measured non-invasively and
cost-efficiently also enabling serial determinations.
Nucleosomes are cell death markers and have been
shown to be useful in the early estimation of che-
motherapy response in lung cancer patients [19-22], as
well as in patients suffering from other solid cancers
[23-26]. In the present study we determined nucleo-
somes and other cell death parameter like cytokeratin-
19 fragments (CYFRA 21-1), lactate dehydrogenase
(LDH), the colorectal tumor related markers carcinoem-
bryonic antigen (CEA) and cancer antigen 19-9 (CA 19-
9) [27], the C-reactive protein (CRP) and classical liver
parameters in the serum of patients undergoing SIRT in
order to identify markers for predicting therapy
response and indicating prognosis.
Materials and Methods
Patients
In the present study cohort, 49 colorectal cancer
patients suffering from liver metastases (33 males and
16 females, median age 62.6 years, range 35-77 years)
treated with SIR therapy at the University Hospital
Munich-Grosshadern between May 2006 and May 2008
were prospectively and consecutively included in the
study. All patients had primarily been treated with surgi-
cal resection and adjuvant chemotherapy (fluoruracil,
folinic acid, oxaliplatin and/or irinotecan) and developed
metachronous liver metastases lateron. Median time
from initial diagnosis to SIRT was 25.1 (5.7-140)
months. Patient characteristics are summarized in
(Table 1).
Inclusion criteria were good performance status
(ECOG ≤1) and no other therapy options available for
the treatment of the liver metastases. Prior to radioem-
bolization, all the patients were assessed with standard
blood tests, whole-body combined positron emission
computed tomography (PET-CT), magnetic resonance
imaging (MRI) of the abdomen and diagnostic hepatic
angiography with application of Technetium 99-macro-
aggregated albumin (Tc-99 m MAA) followed by thor-
acic and abdominal perfusion gamma scintigraphy to
predict microsphere distribution [17].
Exclusion criteria were previous external beam radia-
tion of the liver and recent treatment with capacitebine
[28], significant tumor activity outside the liver, evidence
of insufficient liver function (bilirubin > 2 mg/dL, alanine
aminotransferase (ALT) and aspartate aminotransferase
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50,000/μL, portal vein occlusion and significant hepato-
pulmonary shunting > 20% detected in the Tc-99 m
MAA scan.
The study was approved by the local ethics committee
and written informed consent for additional blood col-
lection and data acquisition was obtained from each
patient before radioembolization.
Treatment procedures
All SIRT procedures were performed under angio-
graphic control (Multistar TOP and Axiom Artis dTA,
Siemens, Munich, Germany) and under local anaesthe-
sia. Using Seldinger technique, a 4-French catheter was
introduced via the femoral artery. After prophylactic
coiling of the gastroduodenal artery and, if necessary, of
the right gastric artery and other small visceral vessels,
the catheter tip was placed distal of the cystic artery at
an identical position as during Tc-99 m MAA applica-
tion. The dosage of SIR-spheres
® was titrated to the cal-
culated extent (Activity [GBq] = BSA - 0,2 + tumor
volume/total liver volume; BSA [m
2] = 0,20247 × height
[m]
0,725 x weight [kG]
0,425) over a time period of 30 to
45 min and administered separately with approximately
two thirds of the dose directed to the right lobe. To
avoid retrograde embolization of non-target areas due to
back spill, sterile water followed by contrast media was
flushes alternatedly to the microspheres [16].
Classification of response to therapy
In all patients, staging investigations consisting of PET-
CT and MRI of the abdomen were performed within a
median of 94 (range 71-125) days after SIRT to evaluate
the response to therapy. As there is currently no
accepted standard for the evaluation of PET-CT images
for solid tumors [29], response to therapy was deter-
mined, as generally conducted in daily routine, by com-
paring the follow-up with pretherapeutical images.
Definition of “progression” was death before staging, the
occurrence of new tumor manifestations in the liver or
in other organs according to the RECIST criteria for
solid tumors [30] with either augmentation in tumor
activity in PET-CT, or increase of the tumor diameter
≥20%. 14 of 49 patients did not meet these criteria and
thus were classified as non-progressive (5 stable disease,
9 partial remission). 10 patients deceased before the
investigations could be performed.
Sample collection and assays
Blood samples were collected prospectively before ther-
apy, three, six, 24 and 48 hours (h) after SIRT. Subse-
quently they were centrifuged at 3,000xG for 15 min
within one to two hours after venous puncture. After
stabilization by adding 10 mM EDTA, sera were stored
at -80°C. Prior to the determination of nucleosomes,
samples were thawed, homogenized and diluted 1:4 with
an incubation buffer. The courses of nucleosomes of
each patient were determined within one run of the
enzyme immunoassay to minimize the methodical
variance.
Quantification of nucleosome concentrations in serum
was done by the Cell Death Detection Elisa
plus of Roche
Diagnostics (Mannheim, Germany). Two monoclonal
mouse antibodies, which are directed against histones
and DNA, respectively, catch the nucleosomes specifi-
cally. The anti-histone antibodies fix the complexes to
the microtiter plate, while the anti-DNA antibody,
which is labelled with peroxidase, reacts with the 2,2’-
azino-di-(3-ethylbenzthiazolin-sulfonate) substrate. The
resulting color development is proportional to the
amount of nucleosomes which are captured in the anti-
body sandwich and enables the photometric
Table 1 Characteristics of patients with colorectal cancer
and liver metastases undergoing SIR therapy
Median Range
Age 62.6 years 35.3 - 77.9 years
Time to SIRT after primary
diagnosis
25 months 6-140
Number Percentage (%)
Patients 49 100
Gender
Female 16 32.7
Male 33 67.3
Localisation of primary tumor
Colon 11 22.5
Sigma 22 44.0
Rectum 16 32.5
Chemotherapies before SIRT
FOLFOX 42 85.7
FOLFIRI 47 95.9
Therapy response
REM 9 18.4
SD 5 10.2
PD 35 71.4
Progression defining
liver metastases 19 54.3
extrahepatic manifestation 6 17.1
deceased 10 28.6
One year survival*
Yes 22 45.8
No 26 54.2
Median 95% Conf.
Interval
Overall survival 8.8
months
5.1-18.1
* one patient lost to follow-up
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established standard [31].
In addition, we determined CYFRA 21-1, CA 19-9 and
CEA in all blood samples by Elecsys 2010, Roche Diag-
nostics. LDH, CRP, AST, ALT, bilirubin, gamma-gluta-
myl-transferase (GGT), alkaline phosphatase (AP),
amylase, lipase and choline esterase (CHE) were mea-
sured by high-end analyzer AU 2700 (Olympus Diagnos-
tics, Hamburg, Germany) in all but the three and six
hours post treatment samples.
Statistics
Concentrations of all measured markers before, three,
six, 24 and 48 h after SIRT as well as their differences
compared to pretherapeutic levels were considered for
statistical evaluation.
Concerning their response to therapy, patients with
partial remission and stable disease were combined into
the ‘no progression’ group. They were compared to
patients who suffered from progressive disease.
For the assessment of significance between marker
levels in therapy response groups, the Wilcoxon test was
used. For analysis of survival time, the marker values
were separated into equal quartiles which were used as
cut-offs in Kaplan-Meier analysis and log-rank test.
In multivariate analyses, all parameters before and 24 h
after SIRT significant in Kaplan-Meier analyses were
included into Cox-Regression models. Generally all values
were logarithmized and entered the multivariate evalua-
tion as continuous variables. As for some parameters few
values were missing (pretherapeutic values: LDH (N = 6),
CHE (N = 3), CYFRA 21-1 (N = 1), AP (N = 3), CA 19-9
and CEA (N = 2), nucleosomes (N = 1); 24 h values: LDH
(N = 2), CA 19-9, CEA and nucleosomes (N = 1), they
were replaced by the medians of the cohort. Calculations
were performed without and with missing values and no
difference in the results were seen. In a first step, only pre-
therapeutic levels of all univariatly significant parameters
(nucleosomes, CYFRA 21-1, AST, GGT, AP, CHE, LDH,
CRP, CA 19-9 and CEA) were combined and all possible
combinations of two or three parameters were tested on
their prognostic value for overall survival. Second, 24 h
values were additionally taken into account in the same
setting. Only those models with all variables being signifi-
cant were considered. Subsequently, performance of the
models was compared by Akaike Information Criterion
(AIC) to identify the most valuable models.
A P-value of < 0.05 was considered statistically signifi-
cant. All calculations were performed by software of
SAS (version 9.2, SAS Institute Inc., Cary, N.C., USA).
Results
Already 24 h after application of SIRT, concentrations of
circulating nucleosomes, CYFRA 21-1, CEA, liver
enzymes and bilirubin were increased whereas GGT,
AP, CHE and activity of lipase and amylase decreased
significantly. LDH, CRP and CA 19-9 remained stable
during the first 24 h and significantly increased 48 h
after SIRT. While this effect was most obvious in cell
death biomarkers such as nucleosomes and CYFRA 21-1
it was less visible in surface cancer biomarkers such as
CEA and CA 19-9 (Table 2).
When evaluating therapy response 3 months after
SIRT, 14 patients out of 49 showed stable disease or par-
tial remission (no progression) while the remaining 35
patients either deceased within time to staging (N = 10),
developed progressive disease in the liver (N = 19) or in
other organs (N = 6). (Table 1) Concerning therapy
response, the pretherapeutical levels of CA 19-9, CEA,
CYFRA 21-1, LDH, CHE and AST showed significant dif-
ferences between both groups. Although pretherapeutical
values of circulating nucleosomes differed not between
responder groups, higher nucleosomes values were mea-
sured 24 h after SIRT in patients with progressive disease
as compared with non-progressive patients (p = 0.0034).
CHE and CA 19-9 were the only markers which showed
significant differences concerning therapy response for
every time point examined (Figure 1, Table 3).
In additiona, several laboratory markers were found to
be associated with the overall survival: When medians,
25th and 75th percentiles were used as cutoffs for the
various markers, values before and 24 h after SIRT of
CEA, CA 19-9, CYFRA 21-1, AST, GGT, AP, CHE,
LDH, Amylase and CRP as well as nucleosomes (24 h)
showed to be significant prognostic markers in univari-
ate analyses (Figure 2B-H, Table 4).
In multivariate Cox regression analyses, all combina-
tions of two or three parameters including all prethera-
peutic values of univariately relevant prognostic markers
were tested resulting in a variety of possible prognostic
models. The lowest and thus best AIC (Akaike Informa-
tion Criterion) value with all parameter still significant
was attained for the combination of CRP with AST.
This model had even higher prognostic power than any
combination of three pretherapeutic parameters. It has
to be emphasized that a similar AIC value was obtained
by the combination of CRP and LDH as well suggesting
that AST is exchangeable with LDH. An even lower
AIC and thus a better prognostic information was
achieved when, in addition, 24 h values of all relevant
markers were considered in Cox analyses. Then, the
combination model of pretherapeutic levels of CRP and
AST and nucleosomes 24 h after SIRT yielded best
prognostic information. (Table 5)
Discussion
The first experiences of radioembolization with Yttrium
90 for patients suffering from liver metastases that
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1964 by Arial and coworkers [32]. However, as radiation
leakage into non-targeted tissues was a non-controllable
problem, the therapy was abandoned until the late
1980s, when new resin and glass microspheres were
developed [33] and pretherapeutical Tc-99 m MAA
scans were able to identify high risk patients for unde-
sirable side effects [17]. Until recently, SIRT was used as
a salvage therapy, when all other treatment options like
surgical treatment, chemotherapy and local ablation
were exhausted [12,16,33,34]. In recent years, some stu-
dies have been published that demonstrated promising
results with positive benefit for patients when SIRT was
combined with chemotherapy [12,34]. In February 2009,
a worldwide multicenter study started comparing com-
bined SIRT with FOLFOX versus FOLFOX alone as a
first-line therapy in colorectal cancer patients with liver
metastases too extensive for surgery [35].
Table 2 Levels of biomarkers before, 3, 6, 24 and 48 h after application of SIRT
Reference value (95th perc. of healthy) 0 hours 3 hours 6 hours 24 hours 48 hours
Median Median Median Median Median
Range Range Range Range Range
Nucleo-somes [ng/mL] 190.5 197.6 237.4 758.5 596.0
<3 6 5.0-1624 34.8-2501 40.7-2064 21.7-4334 51.7-2547
CYFRA 21-1
[ng/mL]
10.9 9.3 8.8 28.6 27.5
< 2.2 0.8-246.0 0.9-240.0 1.1-230.0 1.0-811.0 1.5-638.0
CEA
[ng/mL]
330.0 343.5 356.5 351.0 433.0
< 3.4 2.0-31620 1.9-33010 1.9-16980 1.6-36120 1.6-37550
CA 19-9 [U/mL] 40.0 41.6 49.7 48.7 56.4
<3 7 2.4-11530 2.3-24400 2.2-8748 2.4-18550 2.3-17000
LDH
[U/L]
407.0 486.5 585.0
< 250 178.0-3068 143.0-2923 142.0-3585
CRP
[mg/dL]
1.3 1.3 4.6
< 0.5 0.1-20.3 1.3-21.8 0.1-16.3
CHE
[kU/L]
7.3 6.3 5.9
5.0-13.3 2.8-11.1 2.8-11.1 5.9-10.5
AST
[U/L]
52.0 74.5 68.5
<3 3 24.0-190.0 15.0-339.0 19.0-317.0
ALT
[U/L]
34.5 46.0 48.5
<3 5 15.0-268.0 14.0-178.0 13.0-136.0
Bilirubin
[mg/dL]
0.7 1.0 1.2
< 1.0 0.3-1.9 0.4-2.2 0.4-2.8
AP
[U/L]
160.0 148.0 156.0
< 135 81.0-742.0 63.0-655.0 61.0-630.0
GGT
[U/L]
183.5 165.5 168.5
<3 8 33.0-712.0 31.0-577.0 31.0-653.0
Amylase
[U/L]
58.0 44.0 46.5
< 100 20.0-136.0 20.0-429.0 20.0-519.0
Lipase
[U/L]
26.0 18.0 20.0
<6 0 3.0-263.0 3.0-585.0 3.0-495.0
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may be included into earlier treatment concepts in the
therapeutic management of colorectal cancer patients.
However, there is still only rare information on potential
prognostic parameters for patients undergoing SIR ther-
apy [18]. Such prognostic factors would be highly desir-
able for the pretherapeutic selection of those patients
who will most benefit from SIR therapy. Other sub-
groups of patients who have no or only limited benefit
from radioembolization could be identified [33] to avoid
unnecessary side effects and high expenses without gain-
ing a benefit for the patient.
Furtheron the efficacy of SIRT should be early esti-
mated - if possible already during the first days after the
application - in order to potentially intensify the therapy
strategy i.e. by completing SIRT by chemo- or biological
therapies. As serum-based biomarkers are easily accessi-
ble, cheap and can be determined in serial measure-
ments, they are ideal tools to pretherapeutically predict
the therapy outcome enabling an effective patient
stratification for SIR treatment and to monitor local and
systemic biochemical SIRT effects when determined
repeatedly during the very early phase after SIRT
application.
In this study, a broad panel of biomarkers relevant for
various features of tumor biology and treatment effects
was monitored: CEA and CA 19-9 are well-established
oncological biomarkers used in the follow-up care and
prognosis of colorectal cancer patients [36,37] and CEA
levels are observed to be strongly elevated in cancer
patients suffering from liver metastases [38]. Cell death
markers nucleosomes, CYFRA 21-1 and LDH reflect
pathophysiological processes in strongly proliferating
tumors as well as the cellular and immunological effects
of SIRT on the tumor and the organism as a whole. The
liver markers AST, ALT, GGT, bilirubin, AP and CHE
and the pancreatic enzymes amylase and lipase indicate
t h em o r eo r g a n - s p e c i f i ca l t erations and potential side
effects such as temporary pancreatits due to misguided
microspheres [39]. CRP is frequently used as a marker
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Figure 1 Distribution of serum concentrations of nucleosomes (A), CYFRA 21-1 (B), CEA (C) and CA 19-9 (D) comparing therapy
response groups. ○ Responder; ● Non-Responder.
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Responder Non-Responder
Marker Time [hours] Median Range Median Range p-Value
Nucleosomes
[ng/mL]
0 198.5 17.4-1624 174.7 5.0-1617 0.991
24 239.1 55.6-1225 844.8 21.7-4334 0.003
48 677.2 51.7-2095 594.9 133.3-2547 0.851
CYFRA 21-1
[ng/mL]
0 6.9 0.8-32.8 14.0 1.3-246.0 0.031
24 28.4 1.0-118.0 30.8 2.9-811.0 0.493
48 19.6 1.5-404.0 28.5 2.6-638.0 0.293
CEA
[ng/mL]
0 162.0 4.0-986.0 557.0 2.0-31620 0.037
24 265.5 2.6-5011 540.5 1.6-36120 0.087
48 229.5 2.2-4073 524.0 1.6-37550 0.063
CA 19-9
[U/L]
0 18.6 2.4-159.0 148.0 2.4-11530 0.001
24 17.9 2.5-298.0 158.0 2.4-18550 0.004
48 20.9 2.4-260.0 187.5 2.3-17000 0.002
LDH
[U/L]
0 349.0 178.0-544.0 529.5 220.0-3068 0.011
24 450.0 143.0-1117 532.0 148.0-2923 0.522
48 572.0 142.0-1488 607.5 168.0-3585 0.434
CRP
[mg/dL]
0 0.9 0.3-5.1 2.4 0.1-20.3 0.227
24 1.1 0.1-2.8 2.8 0.2-21.8 0.159
48 4.4 0.1-16.3 4.6 0.3-15.1 0.507
AST
[U/L]
0 37.5 24.0-94.0 56.0 24.0-190.0 0.037
24 111.0 32.0-169.0 69.0 15.0-339.0 0.782
48 85.0 33. 0-179.0 66.0 19.0-317.0 0.912
ALT
[U/L]
0 38.0 15.0-63.0 30.0 15.0-268.0 0.658
24 52.0 26.0-131.0 37.0 14.0-178.0 0.108
48 54.0 23.0-112.0 34.0 13.0-136.0 0.113
GGT
[U/L]
0 183.5 44. 0-432.0 189.0 33.0-712.0 0.782
24 168.5 46.0-391.0 164.0 31.0-577.0 0.965
48 177.5 60.0-406.0 170.0 31.0-653.0 0.903
AP
[U/L]
0 153.0 89.0-569.0 193.0 81.0-742.0 0.559
24 156.0 78.0-588.0 151.0 63.0-655.0 0.707
48 156.0 77.0-504.0 164.0 61. 0-630.0 0.674
Bilirubin
[mg/dL]
0 0.7 0.3-1.4 0.8 0.3-1.9 0.438
24 0.9 0.4-1.7 1.0 0.4-2.2 0.920
48 1.1 0.5-2.4 1.2 0.4-2.8 0.799
CHE
[kU/L]
0 8.3 4.9-11.1 6.5 2.8-10.8 0.017
24 7.1 5.1-11.1 5.7 2.8-10.4 0.009
48 6.9 4.5-10.5 5.3 2.3-9.7 0.006
Amylase
[U/L]
0 64.5 20.0-105.0 54.0 24.0-136.0 0.346
24 45.5 21.0-79.0 44.0 20.0-429.0 0.833
48 50.5 20.0-58.0 46.0 23.0-519.0 0.842
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Lipase
[U/L]
0 27.0 3.0-149.0 25.0 3.0-263.0 0.725
24 17.5 4.0-33.0 18.0 3.0-585.0 0.773
48 16.5 3.0-42.0 22.0 3.0-495.0 0.330
P-values (by Wilcoxon-test) are shown for the various response groups.
There was a significant correlation between therapy response and survival time in this setting (s = 0.034). (Figure 2A).
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Figure 2 Kaplan Meier curves showing the overall survival of patients according to response to therapy (A) (REM = remission; SD =
stable disease; PD = progressive disease) and quartiles of CRP (B), LDH (C), AST (D), CEA (E), CA 19-9 (F), CYFRA 21,1 (G) before
therapy as well as of nucleosomes (H) 24 h after SIRT.
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Page 8 of 14for inflammation, but may also serve as prognostic tool
in cancer patients [40].
The concentrations of all examined parameters
showed significant alterations at least 24 or 48 h after
SIRT. These results were expected for all markers
reflecting high cell turnover by a rapid release and a
short half-life of several hours such as nucleosomes and
CYFRA 21-1 [41]. This phenomenon was less pro-
nounced for the cancer biomarkers CEA and CA 19-9
that are known to be more stable surface parameters
with minor increases and longer half-life times in blood
of 2 to 5 days. Therefore those markers normally are
only considered to be analyzed in two to three months
intervals during the follow-up of patients with colorectal
cancer [42].
Concerning overall survival of colorectal cancer
patients undergoing liver surgery, pretherapeutic CEA
has earlier been reported to be a powerful predictor
[37,38]. Our results are consistent with those findings as
pretherapeutical CEA levels clearly distinguished
between patient groups with different therapy responses
and were predictive for survival time.
In addition, CA 19-9 values before, 24 and 48 h after
SIRT significantly indicated the later therapy outcome
and survival in our setting. Similarly, CA 19-9 levels
have earlier been shown to predict survival in patients
who underwent surgical resection of colorectal cancer
[37] although it is officially not recommended for fol-
low-up care of colorectal cancer patients [36].
While many cancers are characterized by high cellular
turnover including massive cell proliferation and cell
death, the concentration of the cell death end products
nucleosomes in serum varies between different types of
cancers and also between individuals [43,44]. Interest-
ingly, levels of nucleosomes were found to be higher in
advanced tumor stages and in patients with metastasis
of bowel cancer that may be attributed to the increasing
amount of dysfunctional cells [44]. Thus we expected to
find high rates of nucleosomes before, as well as during
therapy. The pretherapeutic median value of nucleo-
somes (191 ng/mL) was considerably higher than in
healthy individuals (36 ng/mL) [23]. Already three and
six hours after SIRT slowly increasing values of nucleo-
somes were detected in most patients followed by a
rapid and significant rise after 24 h; these elevated levels
lasted also until the second day after therapy. Most
notably, increased nucleosome levels 24 h after SIRT
indicated significantly poor therapy response and
reduced survival time. On a first view, these results
appear irritating as an acute and extended induction of
apoptosis after irradiation was reported to lead to
favourable therapy responses particularly in some can-
cers treated in early stages [45] and thus should result
in high nucleosome levels. However, in several settings
of cytotoxic radio- and chemotherapies of patients with
advanced stage cancers, the contrary association was
observed with high nucleosome levels during the first
days after therapy and unfavourable outcome such as in
studies on patients with advanced colorectal [25,26],
pancreatic [24], non-small cell [19,21,22] and small cell
lung cancer [20]. In those settings, non-responding
advanced tumors may have more aggressive features
with high cell turnover and a better blood supply lead-
ing to more effective release of nucleosomes into the
blood or a less effective elimination of nucleosomes
from the circulating due to a weakened or impaired
immune system.
Similar kinetics as for nucleosomes were also observed
for other cell death markers like CYFRA 21-1 and LDH.
Cytokeratin-19 fragments are part of the cell cytoskele-
ton and are released during pathologies with high cell
death rates [41]. CYFRA 21-1 is known as a sensitive
tumor marker that is valuable in supporting the differ-
ential diagnosis, therapy monitoring and estimation of
non-small cell lung cancer and some other cancer enti-
ties, particularly in advanced stages [41,46,47]. CYFRA
21-1 was at high levels already before start of therapy
and considerably increased 24 and 48 h after SIRT.
Interestingly, only the pretherapeutical CYFRA 21-1
values were helpful in indicating poor therapy response
while for the estimation of overall survival all examined
time points yielded significant results. It correlated
clearly with LDH (R > 0.85 for every single point exam-
ined) which also was of important predictive and prog-
nostic value.
CRP is known as a sensitive but non-specific inflam-
matory marker which is induced by IL-6 in the liver. In
addition, it provides strong prognostic information for
overall survival in patients with colorectal cancer under-
going surgery [40] or adjuvant chemotherapy [48]. Also
in our setting, high CRP values had a strongly unfavour-
able prognostic relevance. Interestingly, high AST levels
were as well associated with poor prognosis. That may
be the result of pretherapeutically compromised liver
tissue or a postembolization syndrome after normal liver
tissue damage by SIRT induced ischemia. However,
alterations of ALT levels and concentrations of other
liver parameters were less pronounced and were not as
strongly associated with prognosis of patients.
Joining all univariately significant results for overall
survival into multivariate testing of possible double and
triple marker combinations revealed CRP and AST as
best model of independent prognostic markers available
before start of the therapy. When 24 h values were
added as well, nucleosomes 24 h further improved the
prognostic power of the existing model. This illustrates
that pretherapeutic CRP and AST as well as 24 h
nucleosome levels cover different pathological processes
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Page 9 of 14Table 4 Kaplan-Meier analyses of all parameters with median survival and 95% confidence interval before and 24 h
after SIRT
Biomarker Time Quartile 1 Quartile 2 Quartile 3 Quartile 4 p-value
Median
survival
[months]
95%
Confi.
Interval
Median
survival
[months]
95%
Confi.
Interval
Median
survival
[months]
95%
Confi.
Interval
Median
survival
[months]
95%
Confi.
Interval
Log-
rank
Nucleosomes
[ng/mL]
0 h < 83 83-190 191-415 > 415 0.1275
17.3 1.5 - 8.2 4.6 - 13.8 3.2-23.8 6.0 1.5-15.4
24 h < 384 384-751 752-1232 > 1232 0.0004
23.8 4.9-23.8 8.0 2.5 - 13.8 4.0-20.6 5.1 1.4-6.1
CYFRA 21-1
[ng/mL]
0 h < 5.3 5.3-10.0 10.0-32 > 32.8 < .0001
20.6 8.2 - 4.9 - 7.0 2.8-18.8 3.1 1.4-5.1
24 h < 13 13-28 29-74 > 74 0.0009
20.6 8.2-23.8 6.3 3.4 - 6.2 3.1 - 4.6 1.4-15.0
CEA
[U/L]
0 h < 55 55-320 321-1041 > 1041 0.0002
20.6 3.1 - 19.6 5.6 - 8.3 4.2-18.8 3.1 1.4-6.1
24 h < 85 85-351 352-982 > 982 0.0002
20.6 8.2-23.8 19.6 4.2 - 5.5 2.5-8.8 4.9 1.5-15.0
CA 19-9
[U/L]
0 h < 10 10-40 41-285 > 285 0.0006
15.0 3.1 - 23.8 8.2 - 6.6 2.8 - 4.9 1.4-6.2
24 h < 10 10-48 49-285 > 285 0.0096
15.4 3.1 - 17.8 4.2-23.8 6.6 2.8 - 5.5 1.4-11.0
CRP
[mg/dL]
0 h < 0.5 0.5-1.3 1.4-8.3 > 8.3 < .0001
23.8 19.6 - 14.4 3.4 - 6.8 4.4-15.0 3.1 1.4-5.1
24 h < 0.7 0.7-1.3 1.4-6.4 > 6.4 < .0001
23.8 11.0-23.8 4.7 - 8.8 5.8-15.4 3.0 1.4-5.1
LDH
[U/L]
0 h < 299 299-393 394-604 > 604 < .0001
20.6 8.2 - 15.4 4.7 - 8.8 1.5-23.8 3.2 1.5-5.0
24 h < 336 336-486 487-878 > 878 0.0002
23.8 8.2 - 11.0 4.4 - 6.8 4.6-16.8 2.8 1.4-15.0
AST
[U/L]
0 h < 35 35-52 53-66 > 66 < .0001
20.6 15.0 - 13.8 5.0 - 7.3 4.6-15.0 3.0 1.4-4.2
24 h < 48 48-74 75-135 > 135 0.0004
11.0 - 6.3 4.6-19.6 5.6 2.8-15.4 3.4 1.5-15.0
ALT
[U/L]
0 h < 26 26-34 35-50 > 50 0.0773
18.8 5.2 - 7.8 3.1 - 13.8 5.1-15.4 3.8 1.5-23.8
24 h < 30 30-46 47-64 > 64 0.0824
20.6 5.2 - 5.5 4.4-15.0 15.0 2.6-19.6 4.1 1.5 -
CHE
[kU/L]
0 h < 5.8 5.8-7.3 7.4-8.4 > 8.4 0.0013
5.1 1.5-6.2 5.9 2.8 - 8.2 4.0-19.6 28.8 11.0-23.8
24 h < 5.1 5.1-6.3 6.4-7.6 > 7.6 0.0002
4.7 1.4-6.8 5.4 2.5-20.6 23.8 4.4 - 18.8 8.2 -
GGT
[U/L]
0 h < 110 110-183 184-282 > 282 0.0034
16.7 5.9 - 18.8 4.4-20.6 11.0 2.8-15.4 4.4 2.5-7.8
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other in their prognostic information.
Although the number of patients included in this
study seems to be quite limited, it has to be emphasized
that all patients had similar pathology, received a stan-
dardized therapy in a speciality center for SIR treatment,
were monitored with a very strictly defined protocol
during the early post-treatment period and were corre-
lated with regular, high standard imaging methods after
3 months and follow- up of overall survival. Considering
these preconditions and the low rate of missing values,
this study constitutes a quite informative approach on
the relevance of biomarker levels or changes in the pre-
diction and prognosis of colorectal cancer patients
undergoing SIRT. Three and six hours values were
included in the program not to miss any relevant time
point mirroring the immediate effects of the therapy.
However, while most biomarkers remained stable or
even showed temporary decreases at these times points,
they increased considerably after 24 and 48 h values and
then showed more informative prognostic values in this
setting. Similar results have earlier been obtained in the
monitoring of colorectal and pancreatic cancer patients
during radiochemotherapy [24,25]. It was speculated
that the temporary decline could be explained by post-
damage cell cycle arrest which was followed by delayed
cell death if the therapy induced lesions could not be
repaired any more.
As a further strength of the present study, besides the
completeness of the data, it has to be pointed out that
all preanalytic steps between blood drawing, laboratory
processing, stabilisation and deep-frozen storage of the
samples and later analysis were under full control of the
study personal and followed a strict preanalytic protocol
to avoid any processing delay or in-vitro manipulation
of the samples. Further, the biomarker analyses were
performed by experienced laboratory staff with all sam-
ples of individual patients in one test run to minimize
potential interassay variations and final interassay cross-
plate validations were added as further quality check.
Laboratory testings were conducted independently of
any clinical data collection. Statistical evaluation was
done independently from both laboratory testing and
clinical data collection by the statistic section of the
study center.
According to current standards, the therapy response
was evaluated with PET-CT and MRI in comparison
with pretherapeutic images. The staging was performed
consistently after two to three months after SIRT - with
the exception of a few patients who were evaluated with
some delay due to clinical reasons. This staging period
is generally chosen to closely monitor the macroscopic
changes which often only develop slowly: For example
in 35 patients with hepatocellular carcinoma treated
with SIRT, WHO responses were only seen in 3 patients
after 1 month and increased to 13 patients after half a
Table 4 Kaplan-Meier analyses of all parameters with median survival and 95% confidence interval before and 24 h
after SIRT (Continued)
24 h < 94 94-165 166-274 > 274 0.0101
17.3 6.8 - 12.5 4.4-20.6 15.0 2.8 - 4.8 2.5-7.8
AP
[U/L]
0 h < 114 114 - 160 161 - 321 > 321 < .0001
20.6 8.2 - 18.8 4.6 - 23.8 6.2 3.2 - 4.2 1.5 - 5.5
24 h < 98 98 - 148 149 - 265 > 265 < .0001
23.8 8.2 - 13.8 4.6 - 19.6 7.8 3.4 - 18.8 3.7 4.1 - 6.2
Bilirubin [mg/
dL]
0 h < 0.5 0.5 - 0.7 0.8 - 1.2 > 1.2 0.2393
14.4 4.4 - 11.0 2.8 - 18.8 5.1 - 4.4 1.5 - 15.0
24 h < 0.8 0.8 - 1.0 1.1 - 1.8 > 1.8 0.3335
10.3 4.0 - 19.6 15.4 4.6 - 5.9 2.5 - 8.2 1.5 - 23.8
Amylase
[U/L]
0 h < 44 44 - 58 59 - 75 > 75 0.0102
5.2 1.4 - 18.8 7.5 3.2 - 19.6 17.4 2.5 - 23.8 5.8 -
24 h < 35 35 - 44 44 - 63 > 63 0.0030
5.2 3.2 - 15.4 6.2 3.1 - 15.0 2.8 - 20.6 1.5 -
Lipase
[U/L]
0 h < 13 13 - 26 27 - 38 > 38 0.5314
5.7 1.5 - 18.8 2.8 - 8.8 4.0 - 13.0 3.4 - 19.6
24 h < 10 10- 18 18 - 28 > 28 0.6226
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Page 11 of 14year [49]. Besides the delay until changes are detectable,
CT or MRI staging results often underly technical lim-
itations as alterations of tumor size does not necessarily
reflect tumor response to treatment but may be attribu-
ted to non-specific effects like haemorrhage and peritu-
moral oedema that may be misinterpreted as progressive
disease [33].
Further evaluation according RECIST criteria only
takes into account the change of the largest lesion dia-
meter but not any volumetric measures [30]; further it
mirrors only the changes of tumor size but not the
more important changes of tumor activity that may have
decreased considerably despite stable tumor volume.
An earlier and more precisely evaluation of tumor
response is obtained by using PET-CT as it is a func-
tional body-imaging and thus visualizes not just macro-
scopic but also metabolic changes [50]. Therefore, the
results of PET-CT exams were priorized when evaluating
the therapy response in this study if there were inconsis-
tencies with MRI results in the staging investigations.
Concerning the evaluation of response to this locore-
gional liver-confined SIR therapy, it could be debated
whether only the changes of the therapy-related organ
should be concerned or whether the overall response to
therapy including the development of further intra- or
extrahepatic metastases and tumor-related death should
be respected. As the systemic outcome would be more
relevant for the patient and the marker response in the
blood would more reflect those systemic changes includ-
ing the possible growth of pre-existing micrometastases,
w ec h o s et h i se n d p o i n ta sm o s ti n f o r m a t i v et h e r a p y
outcome.
As further endpoint, overall survival was considered.
Because the patient sample was quite homogeneous and
the clinical characteristics were similar based on the
inclusion criteria to this study, only the dosage of the
microspheres administered and biomarker levels were
examined in relation with survival time. To avoid an
overfitting of the prognostic results to the present data-
set, e.g. by cutoff optimization, the biomarker levels
entered the multivariate analyses as logarithms in a
continuous form. As considerable correlations between
different biomarkers were observed, for example between
AST and LDH, several prognostic scores with similar
strength would be possible in Cox regression analyses.
To avoid the risk to find one specific model by chance,
all possible combinations of two and three markers with
pretherapeutic values alone (model 1) and with prethera-
peutic as well as 24 h values considered (model 2) were
compared by the Akaike Information Criterion (AIC)
indicating the strength of a prognostic model. In this
way, a combination of two pretherapeutic markers (CRP
and AST) was identified as most powerful prognostic
model that would be appropriate for the patient stratifi-
cation for SIR therapy, with a further improvement of the
individual prognostic information by adding the determi-
nation of nucleosomes 24 h after therapy.
Conclusion
To our knowledge this prospective single-center study
on an homogenous colorectal cancer patient cohort
with hepatic metastases treated by SIRT is the first
exploratory, and hypotheses-generating approach to
identify biomarkers during the early treatment phase for
the estimation of prognosis and the early estimation of
therapy response that will be validated by further, larger
prospective treatment studies.
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